Hans‐Georg Kopp

13.7k total citations · 2 hit papers
172 papers, 6.5k citations indexed

About

Hans‐Georg Kopp is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hans‐Georg Kopp has authored 172 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Hans‐Georg Kopp's work include Sarcoma Diagnosis and Treatment (26 papers), Immune Cell Function and Interaction (19 papers) and Gastric Cancer Management and Outcomes (15 papers). Hans‐Georg Kopp is often cited by papers focused on Sarcoma Diagnosis and Treatment (26 papers), Immune Cell Function and Interaction (19 papers) and Gastric Cancer Management and Outcomes (15 papers). Hans‐Georg Kopp collaborates with scholars based in Germany, United States and Switzerland. Hans‐Georg Kopp's co-authors include Helmut R. Salih, Theresa Placke, Shahin Rafii, Andrea T. Hooper, Scott T. Avecilla, Michael Haap, Hans‐Peter Lipp, Jörg Hartmann, Carlos A. Ramos and Lothar Kanz and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Hans‐Georg Kopp

165 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
Engraftment and Reconstitution of Hematopoiesis Is Dependent on VEGFR2-Mediated Regeneration of Sinusoidal Endothelial Cells

2009 467 citations Andrea T. Hooper, Hans‐Georg Kopp et al. profile →

Peers

Countries citing papers authored by Hans‐Georg Kopp

Since Specialization

Citations

This map shows the geographic impact of Hans‐Georg Kopp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Georg Kopp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Georg Kopp more than expected).

Fields of papers citing papers by Hans‐Georg Kopp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Georg Kopp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Georg Kopp. The network helps show where Hans‐Georg Kopp may publish in the future.

Co-authorship network of co-authors of Hans‐Georg Kopp

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Georg Kopp. A scholar is included among the top collaborators of Hans‐Georg Kopp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Georg Kopp. Hans‐Georg Kopp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade 2024 ·Cancers ·Andriani Charpidou, Grigoris Gerotziafas, Sanjay Popat, António Araújo, Arnaud Scherpereel, Hans‐Georg Kopp, Paolo Bironzo, Gilbert Massard, David Jiménez, Anna Falanga, Αναστάσιος Κόλλιας, Konstantinos Syrigos	3
2	Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. 2024 ·Journal of Clinical Oncology ·Rajiv Shah, Martin Reck, Christian Grohé, Daniel C. Christoph, (unknown), Felix Carl Saalfeld, Nikolaj Frost, Hans‐Georg Kopp, Martin Faehling, Frank Griesinger, (unknown), Petra Hoffknecht, Jonas Kuon, (unknown), (unknown), (unknown), Michael Thomas	1
3	BCL-2 and BOK regulate apoptosis by interaction of their C-terminal transmembrane domains 2024 ·EMBO Reports ·(unknown), (unknown), (unknown), Dang Nguyen, (unknown), (unknown), (unknown), Bernhard Gillissen, Walter E. Aulitzky, Hans‐Georg Kopp, Markus Rehm, David W. Andrews, Kristýna Pluháčková, Frank Eßmann	7
4	Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial. 2023 ·Journal of Clinical Oncology ·Rajiv Shah, Laura V. Klotz, Daniel C. Christoph, Karsten Schulmann, Hans‐Georg Kopp, Niels Reinmuth, Michael Ried, Maike de Wit, (unknown), Claas Wesseler, Martin Reck, (unknown), Cornelius F. Waller, Petra Hoffknecht, (unknown), Marc A. Schneider, Rouven Behnisch, Petros Christopoulos, Martin Eichhorn, Michael Thomas	1
5	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG) 2020 ·BMJ Open ·Leopold Hentschel, Stephan Richter, Hans‐Georg Kopp, Bernd Kasper, Annegret Kunitz, Viktor Grünwald, Torsten Keßler, Jens M. Chemnitz, Uwe Pelzer, Ulrich S. Schuler, (unknown), Andrea Schilling, Beate Hornemann, (unknown), Martin Bornhäuser, Markus K. Schuler	6
6	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial breakdown → 2019 ·The Lancet Oncology ·Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo	1137
7	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation 2018 ·Cancer Research ·Markus Löffler, Daniel J. Kowalewski, Linus Backert, Jörg Bernhardt, Patrick Adam, Heiko Schuster, (unknown), (unknown), Hans‐Georg Kopp, Stefan Beckert, Silvia Wagner, Ingmar Königsrainer, Oliver Kohlbacher, Lothar Kanz, Alfred Königsrainer, Hans‐Georg Rammensee, Stefan Stevanović, Sebastian P. Haen	36
8	CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin 2018 ·European Journal of Radiology ·Michael Esser, (unknown), Wolfgang Thaiss, Christian Philipp Reinert, Jan Fritz, Hans‐Georg Kopp, Marius Horger	11
9	The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells 2018 ·Cancer Immunology Immunotherapy ·Daniela Dörfel, Christian Lechner, Simone Joas, (unknown), Michael Gutknecht, (unknown), Julian Geiger, (unknown), Stefanie Maurer, Martin Müller, Hans‐Georg Kopp, Helmut R. Salih, Frank Grünebach, Susanne M. Rittig	8
10	Platelet Programmed Cell Death Ligand 1 (pPDL-1) Is a Prognostic Marker in Advanced Lung Cancer 2017 ·Blood ·Clemens Hinterleitner, (unknown), Stefan Wirths, Stefanie Bugl, Elke Malenke, (unknown), Lothar Kanz, Hans‐Georg Kopp	1
11	Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO) 2017 ·Annals of Oncology ·Salah‐Eddin Al‐Batran, Claudia Pauligk, Nils Homann, Harald Schmalenberg, Hans‐Georg Kopp, Georg Martin Haag, (unknown), H. S. Wolff, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, (unknown), Jörg Trojan, Thorsten Oliver Goetze, Jens Meiler, (unknown), Elke Jäger, Ralf‐Dieter Hofheinz	18
12	RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia 2012 ·Cancer Research ·Benjamin Joachim Schmiedel, (unknown), Tina Nuebling, Hans‐Georg Kopp, Stefan Wirths, Miyuki Azuma, Pascal Schneider, Gundram Jung, Ludger Große‐Hovest, Helmut R. Salih	49
13	Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling 2012 ·Blood ·Stefanie Bugl, Stefan Wirths, Markus P. Radsak, Hansjörg Schild, Pamela Stein, Maya C. André, Martin Müller, Elke Malenke, Tina Wiesner, Melanie Märklin, Julia-Stefanie Frick, Rupert Handgretinger, Hans‐Georg Rammensee, Lothar Kanz, Hans‐Georg Kopp	78
14	Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells 2011 ·Cancer Research ·Theresa Placke, Melanie Örgel, Martin Schaller, Gundram Jung, Hans‐Georg Rammensee, Hans‐Georg Kopp, Helmut R. Salih	350
15	Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors 2010 ·Journal of Cancer Research and Clinical Oncology ·Hans‐Georg Kopp, Stefan Wirths, Christoph Faul, Wolfgang Bethge, Stefan Scheding, Wolfram Brugger, Lothar Kanz, Wichard Vogel	2
16	Wnt1 Overexpression Leads to Enforced Cardiomyogenesis and Inhibition of Hematopoiesis in Murine Embryonic Stem Cells 2009 ·Stem Cells and Development ·Katja Weisel, Hans‐Georg Kopp, Malcolm A.S. Moore, Lorenz Studer, Tiziano Barberi	9
17	Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization 2006 ·Journal of Clinical Investigation ·Hans‐Georg Kopp, Andrea T. Hooper, M. Johan Broekman, Scott T. Avecilla, Isabelle Petit, Min Luo, Till Milde, Carlos A. Ramos, Fan Zhang, (unknown), Paul Börnstein, David Jin, Aaron J. Marcus, Shahin Rafii	80
18	Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens 2002 ·Journal of Cancer Research and Clinical Oncology ·Wichard Vogel, Hans‐Georg Kopp, Lothar Kanz, Hermann Einsele	18
19	[Further studies on antihelmintic treatment of ruminants in zoological gardens with mebendazole]. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), Hans‐Georg Kopp, Hartmut Wiesner	1
20	[Hand-foot-mouth disease. A new exanthematous childhood disease]. 1966 ·PubMed ·N Hjorth, Hans‐Georg Kopp	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact